SAN DIEGO--(BUSINESS WIRE)--According to a health economics study published online in The American Journal of Managed Care, bioTheranostics’ Breast Cancer IndexSM molecular test is associated with lower medical costs when used either at diagnosis or at five years post-diagnosis in estrogen receptor-positive (ER+) breast cancer patients.
The study—the first to look at the economic impact of the Breast Cancer Index—evaluated the cost utility of the test from a U.S. third-party payor perspective, assessing the economic impact of implementing the assay in a population of ER+ patients at diagnosis and five years post-diagnosis compared with standard practice. The Breast Cancer Index is a second-generation gene expression test that has been shown in clinical studies to predict risk of both early (0-5 years) and late (5-10 years) breast cancer recurrence, as well as likelihood of benefit from extended endocrine therapy.
Help employers find you! Check out all the jobs and post your resume. v
